{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:porgaviximab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03374943: Phase 1 Interventional Completed Glioblastoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00770354: Phase 2 Interventional Terminated Breast Carcinoma
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02144389: Not Applicable Interventional Completed Schistosomiasis
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:rivabazumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02564744: Phase 2 Interventional Completed Diffuse Large B-Cell Lymphoma
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02410356: Phase 3 Interventional Terminated Growth Hormone Deficiency
(2015)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT00351767: Phase 2 Interventional Completed Foot Ulcer, Diabetic
(2006)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03708224: Phase 2 Interventional Recruiting Cancer
(2019)
Source URL:
Class:
PROTEIN
